Machado-Joseph disease/spinocerebellar ataxia type 3

Handbook of Clinical Neurology

Volumn 103, Issue , 2012, Pages 437-449

  Paulson, Henry ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79961135379     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-51892-7.00027-9     Document Type: Chapter

References (135)

1. Arrasate M., Mitra S., Schweitzer E.S., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
2. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555.
3. Berke S.J., Schmied F.A., Brunt E.R., et al. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem 2004, 89:908-918.
4. Berke S.J., Chai Y., Marrs G.L., et al. Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3. J Biol Chem 2005, 280:32026-32034.
5. Bevivino A.E., Loll P.J. An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta-fibrils. Proc Natl Acad Sci U S A 2001, 98:11955-11960.
6. Bichelmeier U., Schmidt T., Hübener J., et al. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci 2007, 27:7418-7428.
7. Bowman A.B., Yoo S.Y., Dantuma N.P., et al. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet 2005, 14:679-691.
8. Boy J., Schmidt T., Wolburg H., et al. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Hum Mol Genet 2009, 18:4282-4295.
9. Boy J., Schmidt T., Schumann U., et al. A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats. Neurobiol Dis 2010, 37:284-293.
10. Buhmann C., Bussopulos A., Oechsner M. Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. Mov Disord 2003, 18:219-221.
11. Burnett B., Li F., Pittman R.N. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet 2003, 12:3195-3205.
12. Burnett B.G., Pittman R.N. The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proc Natl Acad Sci U S A 2005, 102:4330-4335.
13. Cancel G., Abbas N., Stevanin G., et al. Marked phenotypic heterogeneity associated with expansion of a CAG repeat sequence at the spinocerebellar ataxia 3/Machado-Joseph disease locus. Am J Hum Genet 1995, 57:809-816.
14. Cemal C.K., Carroll C.J., Lawrence L., et al. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet 2002, 11:1075-1094.
15. Chai Y., Koppenhafer S.L., Shoesmith S., et al. Evidence of proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet 1999, 8:673-682.
16. Chai Y., Wu L., Griffin J.D., et al. The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J Biol Chem 2001, 276:44889-44897.
17. Chai Y., Shao J., Miller V.M., et al. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc Natl Acad Sci U S A 2002, 99:9310-9315.
18. Chai Y., Berke S.S., Cohen R.E., et al. Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J Biol Chem 2004, 279:3605-3611.
19. Chen S., Ferrone F.A., Wetzel R. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc Natl Acad Sci U S A 2002, 99:11884-11889.
20. Chow M.K., Mackay J.P., Whisstock J.C., et al. Structural and functional analysis of the Josephin domain of the polyglutamine protein ataxin-3. Biochem Biophys Res Commun 2004, 322:387-394.
21. Do Carmo Costa M., Gomes-da-Silva J., Miranda C.J., et al. Genomic structure, promoter activity, and developmental expression of the mouse homologue of the Machado-Joseph disease (MJD) gene. Genomics 2004, 84:361-373.
22. Donaldson K.M., Li W., Ching K.A., et al. Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc Natl Acad Sci U S A 2003, 100:8892-8897.
23. Doss-Pepe E.W., Stenroos E.S., Johnson W.G., et al. Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol Cell Biol 2003, 23:6469-6483.
24. Durr A., Stevanin G., Cancel G., et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular and neuropathological features. Ann Neurol 1996, 39:490-499.
25. Etchebehere E., Cendes F., Lopes-Cendes I., et al. Brain single-photon emission computed tomography and magnetic resonance imaging in Machado-Joseph Disease. Arch Neurol 2001, 58:1257-1263.
26. Evert B.O., Wullne U., Schulz J.B., et al. High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. Hum Mol Genet 1999, 8:1169-1176.
27. Evert B.O., Vogt I.R., Vieira-Saecker A.M., et al. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. J Neuropathol Exp Neurol 2003, 62:1006-1018.
28. Friedman J.H. Presumed rapid eye movement behavior disorder in Machado-Joseph disease (spinocerebellar ataxia type 3). Mov Disord 2002, 17:1350-1353.
29. Friedman J.H., Fernandez H.H., Sudarsky L.R. REM behavior disorder and excessive daytime somnolence in Machado-Joseph disease (SCA-3). Mov Disord 2003, 18:1520-1522.
30. Gaspar C., Lopes-Cendes I., Hayes S., et al. Ancestral origins of the Machado-Joseph disease mutation: a worldwide haplotype study. Am J Hum Genet 2001, 68:523-528.
31. Goti D., Katzen S.M., Mez J., et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci 2004, 24:10266-10279.
32. Gu W., Ma H., Wang K., et al. The shortest expanded allele of the MJD1 gene in a Chinese MJD kindred with autonomic dysfunction. Eur Neurol 2004, 52:107-111.
33. Gunawardena S., Goldstein L.S. Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol 2005, 62:46-51.
34. Gunawardena S., Her L.S., Brusch R.G., et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyglutamine proteins in Drosophila. Neuron 2003, 40:25-40.
35. Gwinn-Hardy K., Singleton A., O'Suilleabhain P., et al. Spinocerebellar ataxia type 3 phenotypically resembling Parkinson disease in a black family. Arch Neurol 2001, 58:296-299.
36. Harper S.Q., Staber P.D., He X., et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A 2005, 102:5820-5825.
37. Hersch S., Gevorkian S., Marder K., et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006, 66:250-252.
38. Hofmann K., Falquet L. A ubiquitin-interacting motif conserved in components of the proteasomal and lysosomal protein degradation systems. Trends Biochem Sci 2001, 6:347-350.
39. Ichikawa Y., Goto J., Hattori M., et al. The genomic structure and expression of MJD, the Machado-Joseph disease gene. J Hum Genet 2001, 46:413-422.
40. Igarashi S., Takiyama Y., Cancel G., et al. Intergenerational instability of the CAG repeat of the gene for Machado-Joseph disease (MJD1) is affected by the genotype of the normal chromosome: implications for the molecular mechanisms of the instability of the CAG repeat. Hum Mol Genet 1996, 5:923-932.
41. Ikeda H., Yamaguchi M., Sugai S., et al. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet 1996, 13:196-202.
42. Iranzo A., Munoz E., Santamaria J., et al. REM sleep behavior disorder and vocal cord paralysis in Machado-Joseph disease. Mov Disord 2003, 18:1179-1183.
43. Jana N.R., Nukina N. Misfolding promotes the ubiquitination of polyglutamine-expanded ataxin-3, the defective gene product in SCA3/MJD. Neurotox Res 2004, 6:523-533.
44. Jardim L., Pereira M., Silveira I., et al. Neurologic findings in Machado-Joseph disease. Arch Neurol 2001, 58:899-904.
45. Kawaguchi Y., Okamoto T., Taniwaki M., et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994, 8:221-228.
46. Kawai Y., Takeda A., Abe Y., et al. Cognitive impairments in Machado-Joseph disease. Arch Neurol 2004, 61:1757-1760.
47. Kayed R., Head E., Thompson J.L., et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
48. Klockgether T., Ludtke R., Kramer B., et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 1998, 121:589-600.
49. Klockgether T., Skalej M., Wedekind D., et al. Autosomal dominant cerebellar ataxia type I. MRI based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia type 1, 2 and 3. Brain 1998, 121:1687-1693.
50. Koeppen A.H., Dickson A.C., Lamarche J.B., et al. Synapses on the hereditary ataxias. J Neuropathol Exp Neurol 1999, 58:748-764.
51. La Spada A.R., Taylor J.P. Polyglutamines placed into context. Neuron 2003, 38:681-684.
52. Lerer I., Merims D., Abeliovich D., et al. Machado-Joseph disease: correlation between clinical features, the CAG repeat length and homozygosity for the mutation. Eur J Hum Genet 1996, 4:3-7.
53. Lin K.P., Soong B.W. Peripheral neuropathy of Machado-Joseph disease in Taiwan: a morphometric and genetic study. Eur Neurol 2002, 48:210-217.
54. Maciel P., Gaspar C., DeStefano A.L., et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet 1995, 57:54-61.
55. Maciel P., Lopes-Cendes I., Kish S., et al. Mosaicism of the CAG repeat in CNS tissue in relation to age at death in spinocerebellar ataxia type 1 and Machado-Joseph disease patients. Am J Hum Genet 1997, 60:993-996.
56. Mao Y., Senic-Matuglia F., Di Fiore P.P., et al. Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. Proc Natl Acad Sci U S A 2005, 102:12700-12705.
57. Maruff P., Tyler P., Burt T., et al. Cognitive deficits in Machado- Joseph disease. Ann Neurol 1996, 40:421-427.
58. Masino L., Musi V., Menon R.P., et al. Domain architecture of the polyglutamine protein ataxin-3: a globular domain followed by a flexible tail. FEBS Lett 2003, 549:21-25.
59. Masino L., Nicastro G., Menon R.P., et al. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3. J Mol Biol 2004, 344:1021-1035.
60. Matilla T., McCall A., Subramony S.H., et al. Molecular clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease. Ann Neurol 1995, 38:68-72.
61. Matsumura R., Takayanagi T., Fujimoto Y., et al. The relationship between trinucleotide repeat length and phenotypic variation in Machado-Joseph disease. J Neurol Sci 1996, 139:52-57.
62. Matsumura R., Takayanagi T., Murata K., et al. Relationship between (CAG)nC configuration to repeat instability of the Machado-Joseph disease gene. Hum Genet 1996, 98:643-645.
63. Miller V.M., Xia H., Marrs G.L., et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci U S A 2003, 100:7195-7200.
64. Monoi H., Futaki S., Kugimiya S., et al. Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. Biophys J 2000, 78:2892-2899.
65. Moseley M.L., Benzow K.A., Schut L.J., et al. Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology 1998, 51:1666-1671.
66. Muchowski P.J., Wacker J.L. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005, 6:11-22.
67. Munoz E., Rey M.J., Mila M., et al. Intranuclear inclusions, neuronal loss and CAG mosaicism in two patients with Machado-Joseph disease. J Neurol Sci 2002, 200:19-25.
68. Murata Y., Yamaguchi S., Kawakami H., et al. Characteristic magnetic resonance imaging findings in Machado-Joseph disease. Arch Neurol 1998, 55:33-37.
69. Nicastro G., Menon R.P., Masino L., et al. The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. Proc Natl Acad Sci U S A 2005, 102:10493-10498.
70. Nihiyama K., Murayama S., Goto J., et al. Regional and cellular expression of the Machado-Joseph disease gene in brains of normal and affected individuals. Ann Neurol 1996, 40:776-781.
71. Onodera O., Idezuka J., Igarashi S., et al. Progressive atrophy of cerebellum and brainstem as a function of age and size of the expanded CAG repeats in the MJD1 gene in Machado-Joseph Disease. Ann Neurol 1998, 43:288-296.
72. Padiath Q.S., Srivastava A.K., Roy S., et al. Identification of a novel 45 repeat unstable allele associated with a diseasephenotype at the MJD1/SCA3 locus. Am J Med Genet B Neuropsychiatr Genet 2005, 133:124-126.
73. Paulson H.L., Das S.S., Crino P.B., et al. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol 1997, 41:453-462.
74. Paulson H.L., Perez M.K., Trottier Y., et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997, 19:333-344.
75. Perez M.K., Paulson H.L., Pendse S.J., et al. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J Cell Biol 1998, 143:1457-1470.
76. Perez K.P., Paulson H.L., Pittman R.N. Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix. Hum Mol Genet 1999, 8:2377-2385.
77. Pujana M.A., Corral J., Gratacos M., et al. Spinocerebellar ataxias in Spanish patients: genetic analysis of familial and sporadic cases. The Ataxia Study Group. Hum Genet 1999, 104:516-522.
78. Ranum L.P.W., Lundgren J.K., Schut L.J., et al. Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive or sporadic ataxia. Am J Hum Genet 1995, 57:603-608.
79. Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat Med 2004, 10:S10-S17.
80. Rub U., de Vos R.A., Brunt E.R., et al. Degeneration of the external cuneate nucleus in spinocerebellar ataxia type 3 (Machado-Joseph disease). Brain Res 2002, 953:126-134.
81. Rub U., de Vos R.A., Schultz C., et al. Spinocerebellar ataxia type 3 (Machado-Joseph disease): severe destruction of the lateral reticular nucleus. Brain 2002, 125:2115-2124.
82. Rub U., Brunt E.R., Gierga K., et al. The nucleus raphe interpositus in spinocerebellar ataxia type 3 (Machado-Joseph disease). J Chem Neuroanat 2003, 25:115-127.
83. Rub U., Brunt E.R., de Vos R.A., et al. Degeneration of the central vestibular system in spinocerebellar ataxia type 3(SCA3) patients and its possible clinical significance. Neuropathol Appl Neurobiol 2004, 4:402-414.
84. Rub U., Burk K., Schols L., et al. Damage to the reticulotegmental nucleus of the pons in spinocerebellar ataxiatype 1, 2, and 3. Neurology 2004, 63:1258-1263.
85. Rubinsztein C., Leggo J., Coetzee G.A., et al. Sequence variation and size ranges of CAG repeats in the Machado-Joseph disease, spinocerebellar ataxia type 1 and androgen receptor genes. Hum Mol Genet 1995, 4:1585-1590.
86. Saleem Q., Choudhry S., Mukerji M., et al. Molecular analysis of autosomal dominant hereditary ataxias in the Indian population: high frequency of SCA2 and evidence for a common founder mutation. Hum Genet 2000, 106:179-187.
87. Sasaki H., Wakisaka A., Fukazawa T., et al. CAG repeat expansion of Machado-Joseph disease in the Japanese: analysis of the repeat instability for parental transmission, and correlation with disease phenotype. J Neurol Sci 1995, 133:128-133.
88. Scheel H., Tomiuk S., Hofmann K. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Hum Mol Genet 2003, 12:2845-2852.
89. Scherzinger E., Lurz R., Turmaine M., et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997, 90:549-558.
90. Schmidt T., Landwehrmeyer B., Schmitt I., et al. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA 3 patients. Brain Pathol 1998, 8:669-679.
91. Schmidt T., Lindenberg K.S., Krebs A., et al. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol 2002, 51:302-310.
92. Schmitt I., Evert B.O., Khazneh H., et al. The human MJD gene: genomic structure and functional characterization of the promoter region. Gene 2003, 314:81-88.
93. Schols L. Machado-Joseph disease mutation as the genetic basis of most spinocerebellar ataxias in Germany. J Neurol Neurosurg Psychiatry 1995, 59:49-50.
94. Schols L., Amoiridis G., Epplen J.T., et al. Relations between genotype and pheotype in German patients with the Machado-Joseph disease mutation. J Neurol Neurosurg Psychiatry 1996, 61:466-470.
95. Schols L., Haan J., Riess O., et al. Sleep disturbance in spinocerebellar ataxias. Is the SCA3 mutation a cause of restless legs syndrome?. Neurology 1998, 51:1603-1607.
96. Sequeiros J., Coutinho P. Epidemiology and clinical aspects of Machado-Joseph disease. Adv Neurol 1993, 61:139-153.
97. Silveira I., Lopes-Cendes I., Kish S., et al. Frequency of spinocerebellar ataxia type I, dentatorubrual-pallidoluysian atrophy and Machado-Joseph disease mutations in a large group of spinocerebellar ataxia patients. Neurology 1996, 46:214-218.
98. Silveira I., Miranda C., Guimaraes L., et al. Trinucleotide repeats in 202 families with ataxia: a small expanded (CAG)n allele at the SCA17 locus. Arch Neurol 2002, 59:623-629.
99. Soong B.W., Lin K.P. An electrophysiologic and pathologic study of peripheral nerves in individuals with Machado-Joseph disease. Chin Med 1998, 61:181-187.
100. Soong B.W., Cheng C.H., Liu R.S., et al. Machado-Joseph disease: clinical, molecular, and metabolic characterization in Chinese kindreds. Ann Neurol 1997, 41:446-452.
101. Soong B., Lu Y., Choo K., et al. Frequency analysis of autosomal dominant cerebellar ataxias in Taiwanese patients and clinical and molecular characterization of spinocerebellar ataxia type 6. Arch Neurol 2001, 58:1105-1109.
102. Storey E., du Sart D., Shaw J., et al. Frequency of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Australian patients with spinocerebellar ataxia. Am J Med Genet 2000, 95:351-357.
103. Subramony S.H., Currier R.D. Intrafamilial variability in Machado-Joseph disease. Mov Disord 1996, 11:741-743.
104. Subramony S.H., Hernandez D., Adam A., et al. Ethnic differences in the expression of neurodegenerative disease:Machado-Joseph disease in Africans and Caucasians. Mov Disord 2002, 17:1068-1071.
105. Suenaga T., Matsushima H., Nakamura S., et al. Ubiquitin-immunoreactive inclusions in anterior horn cells and hypoglossal neurons in a case with Joseph's disease. Acta Neuropathol (Berl) 1993, 85:341-344.
106. Sugars K.L., Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet 2003, 19:233-238.
107. Tait D., Riccio M., Sittler A., et al. Ataxin-3 is transported into the nucleus and associates with the nuclear matrix. Hum Mol Genet 1998, 7:991-997.
108. Takano H., Cancel G., Ikeuchi T., et al. Close association between prevalence of dominantly inherited spinocerebellar ataxias with CAG-repeat expansions and frequencies of large normal CAG alleles in Japanaese and Caucasian populations. Am J Hum Genet 1998, 63:1060-1066.
109. Takiyama Y., Okynagi S., Kawashima S., et al. A clinical and pathologic study of a large Japanese family with Machado-Joseph disease tightly linked to the DNA markers on chromosome 14q. Neurology 1994, 44:1302-1308.
110. Takiyama Y., Igarashi S., Rogaeva E.A., et al. Evidence for intergenerational istability in the CAG repeat in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. Hum Mol Genet 1995, 4:1137-1146.
111. Takiyama Y., Sakoe K., Nakano I., et al. Machado-Joseph disease: cerebellar ataxia and autonomic dysfunction in a patient with the shortest known expanded allele (56 CAG repeat units) of the MJD1 gene. Neurology 1997, 49:604-606.
112. Taylor J.P., Hardy J., Fischbeck K.H. Toxic proteins in neurodegenerative disease. Science 2002, 296:1991-1995.
113. Toulouse A., Au-Yeung F., Gaspar C., et al. Ribosomal frameshifting on MJD-1 transcripts with long CAG tracts. Hum Mol Genet 2005, 14:2649-2660.
114. Trottier Y., Cancel G., An-Gourfinkel I., et al. Heterogeneous intracellular localization and expression of ataxin-3. Neurobiol Dis 1998, 5:335-347.
115. Tsai H.F., Liu C.S., Leu T.M., et al. Analysis of trinucleotide repeats in different SCA loci in spinocerebellar ataxia patients and in normal population of Taiwan. Acta Neurol Scand 2004, 109:355-360.
116. Tsai H.F., Tsai H.J., Hsieh M. Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells. Biochem Biophys Res Commun 2004, 324:1274-1282.
117. Tuite P.J., Rogaeva E.A., St George-Hyslop P.H., et al. Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. Ann Neurol 1995, 38:684-687.
118. Uchihara T., Iwabuchi K., Funata N., et al. Attenuated nuclear shrinkage in neurons with nuclear aggregates - a morphometricstudy on pontine neurons of Machado-Joseph disease brains. Exp Neurol 2002, 178:124-128.
119. Van Alfen N., Sinke R., Zwarts M., et al. Intermediate CAG repeat lengths (53, 54) for MJD/SCA3 are associated with an abnormal phenotype. Ann Neurol 2001, 49:805-808.
120. Venkatraman P., Wetzel R., Tanaka M., et al. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 2004, 14:95-104.
121. Wang G., Keiko I., Nukina N., et al. Machado-Joseph disease gene product identified in lymphocytes and brain. Biochem Biophys Res Commun 1997, 233:476-479.
122. Warrick J.M., Paulson H.L., Gray-Board G.L., et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in drosophila. Cell 1998, 93:1-20.
123. Warrick J.M., Chan H.Y., Gray-Board G.L., et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 1999, 23:425-428.
124. Warrick J.M., Morabito L.M., Bilen J., et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell 2005, 18:37-48.
125. Watanabe H., Tanaka F., Matsumoto M., et al. Frequency analysis of autosomal dominant cerebellar ataxias in Japanese patietns and clinical characterization of spinocerebellar ataxia 6. Clin Genet 1998, 53:13-19.
126. Williams A.J., Paulson H.L. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci 2008, 31:521-528.
127. Williams A.J., Knutson T.M., Colomer Gould V.F., et al. In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70 interacting protein (CHIP) supports an aggregation model of pathogenesis. Neurobiol Dis 2009, 33:342-353.
128. Willingham S., Outeiro T.F., DeVit M.J., et al. Yeast genes that enhance the toxicity of a mutant huntington fragment or alpha-synuclein. Science 2003, 302:1769-1772.
129. Winborn B.J., Travis S.M., Todi S.V., et al. The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J Biol Chem 2008, 283:26436-26443.
130. Xia H., Mao Q., Eliason S.L., et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004, 10:816-820.
131. Yang W., Dunlap J.R., Andrews R.B., et al. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 2002, 11:2905-2917.
132. Zawacki T.M., Grace J., Friedman J.H., et al. Executive and emotional dysfunction in Machado-Joseph disease. Mov Disord 2002, 17:1004-1010.
133. Zhou L.S., Fan M.Z., Yang B.X., et al. Machado-Joseph disease in four Chinese pedigrees: molecular analysis of 15 patients including two juvenile cases and clinical correlations. Neurology 1997, 48:482-485.
134. Zhou X.Y., Takiyama Y., Igarashi S., et al. Spinocerebellar ataxia type 1 in China. Arch Neurol 2001, 58:789-794.
135. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000, 23:217-247.